Aytu Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Aytu Biopharma

12/05/2025 21:51

Aytu Biopharma Inc AYTU.OQ AYTU.O is expected to show a fall in quarterly revenue when it reports  results on May 14 for the period ending March 31 2025

The Denver Colorado-based  company is expected to report a 23.6% decrease in revenue to $13.739 million from $17.99 million a year ago, according to the estimate from one analyst, based on LSEG data.

​LSEG's mean analyst estimate for Aytu Biopharma Inc is for a loss of 17 cents per share.

The one available analyst rating on the shares is "buy".

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00​, above​ its last closing price of $1.25. ​​​

This summary was machine generated May 12 at 20:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)